GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (MEX:AXNX) » Definitions » Net Income Including Noncontrolling Interests

Axonics (MEX:AXNX) Net Income Including Noncontrolling Interests : MXN-263 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Axonics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Axonics's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was MXN-317 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was MXN-263 Mil.

Axonics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Axonics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics Net Income Including Noncontrolling Interests Chart

Axonics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial -1,507.57 -1,092.37 -1,642.49 -1,163.87 -103.34

Axonics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -166.70 -125.87 68.42 111.59 -317.19

Axonics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-263 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axonics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Axonics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Axonics (MEX:AXNX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (MEX:AXNX) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
LIVN IRTC ITGR IART CNMD PACB GKOS NARI INMD NVCR ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
AXNX:USA
Address
26 Technology Drive, Irvine, CA, USA, 92618
Website
https://www.axonics.com
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.